Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...

Illumina gains after expanding Labcorp collaboration to boost NGS oncology adoption, broaden testing access, and drive growth ...

SAN DIEGO, Feb. 3, 2026 — Illumina (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)’s Frozen Zoo®. The 50-year-old biobank is the world’s most ...

Illumina’s fair value estimate has been adjusted slightly, moving from US$135.94 to US$136.05, signaling only a very modest change in the modeled price target. That small shift sits against a backdrop ...

Shares of IlluminaILMN have risen 44.8% over the past year, reflecting strong momentum. The stock has outpaced the industry’s ...

Illumina has unveiled a new spatial technology that is designed to unlock further sequencing capabilities for researchers.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

San Diego-based Illumina, a global leader in genomic sequencing technology, unveiled its latest machines that could make analyzing genetics cheaper, more efficient and more accessible to researchers.

Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples Sequencing connects decades of preserved biodiversity ...